How is PEG-MGF dosed and mixed?

300 mcg of PEG-MGF (Pegylated Mechano Growth Factor) from a 2 mg vial mixed with 2 mL is 30 units on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water2 mL of water3 mL of water
2 mg2 mg/mL: 200 mcg is 10 units, 300 mcg is 15 units, 400 mcg is 20 units1 mg/mL: 200 mcg is 20 units, 300 mcg is 30 units, 400 mcg is 40 units0.667 mg/mL: 200 mcg is 30 units, 300 mcg is 45 units, 400 mcg is 60 units

No label or human trial dose for PEG-MGF turned up in searches; a 2026 review by Dominikowski and colleagues reports forum-sourced doses of 200–400 µg, subcutaneous or intramuscular, 2–3×/week after exercise, and a forum maintenance figure of 200–400 µg/day.1

Vial, water and syringe units

No label, regulator page or maker leaflet in the evidence gives a PEG-MGF vial strength, which water to mix it with or how much water to add. The table above is arithmetic for an example vial, not a sourced strength.

As a worked example, 300 mcg from a 2 mg vial mixed with 2 mL of water is 1 mg/mL, or 0.3 mL, which is 30 units on a U-100 syringe.

300 mcg of PEG-MGF (Pegylated Mechano Growth Factor) from a 2 mg vial mixed with 2 mL is 30 units on a U-100 syringe.

300 mcg of PEG-MGF (Pegylated Mechano Growth Factor) from a 2 mg vial mixed with 2 mL is 30 units on a U-100 syringe.

Doses and schedules reported

No label or human trial dose for PEG-MGF turned up in searches of DailyMed, ClinicalTrials.gov and PubMed. Every figure below is forum-sourced as reported in one review, which says no peer-reviewed clinical studies report specific dosing regimens in humans.1

The forum figures it reports are 200–400 µg, subcutaneous or intramuscular, 2–3×/week after exercise (30–60 min after training); a loading protocol of 100 µg for 2 weeks, then 200 µg for 2 weeks, then 300 µg for 4 weeks; and maintenance of 200–400 µg/day, with cycles of 8–16 weeks and about a 4-week washout.1 It adds that no peer-reviewed human study has reported a route of administration, and that the half-life is not reported.1

The review also says many of the peptides it covers circulate outside standard medical oversight, with uncertain purity, dose consistency and sterility.1

Milligram has no logged PEG-MGF dose or vial share to report.

Storage before and after mixing

No label or maker leaflet in the evidence gives PEG-MGF storage conditions before or after mixing.

Frequently asked questions

Is there a label or regulator approval for PEG-MGF?

The review states there is an absence of regulatory approval for physique- or performance-related indications of these peptides.1 A 2026 article by the law firm Frier Levitt reports the FDA was removing PEG-MGF from Category 2 (“Bulk Drug Substances that Raise Significant Safety Concerns”) of its interim 503A Bulks List, with separate advisory-committee consultation slated before the end of February 2027, and says the announcement does not indicate it will be placed on the Category 1 “May Compound” list.2

Have human trials tested PEG-MGF or MGF?

The review places PEG-MGF in a tier with no peer-reviewed human studies.1 A ClinicalTrials.gov search returned no PEG-MGF or MGF trial.

References

  1. Frontiers in Endocrinology. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. 2026. pmc.ncbi.nlm.nih.gov
  2. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List - Frier Levitt FDA Peptide Update 2026: Removal from “Do Not Compound” List and What It Means for Pharmacies. 2026. frierlevitt.com